Navigation Links
Genencor Appoints New Executive Vice President - Technical Enzymes
Date:10/1/2007

Glenn E. Nedwin, Ph.D., MBA to Join Genencor's Senior Management Team

ROCHESTER, N.Y., Oct. 1 /PRNewswire/ -- Genencor, a division of Danisco A/S, today announced that Dr. Glenn E. Nedwin will join the Division as Executive Vice President - Technical Enzymes, effective Oct. 1, 2007. As a member of the Genencor Senior Management Team, Dr. Nedwin will head the division's activities in Grain Processing (which includes current fuel ethanol business), Textiles, Specialties & Market Development. He will report directly to Genencor's CEO Tjerk de Ruiter.

Dr. Nedwin comes to Genencor from being Interim President and Chief Science Officer at Dyadic International, Inc., a biotech company active in the bioenergy and industrial enzymes fields. Prior to joining Dyadic, Dr. Nedwin was President of Novozymes, Inc., where he established the company's US R&D headquarters for Novozymes A/S, as well being active in business development. In addition to his 14+ years with Novozymes, his career has included key positions with XOMA Corporation, Ideon Corporation, Molecular Therapeutics, Inc., and Genentech, Inc.

Dr. Nedwin's appointment continues to enhance Genencor's world-class, organization and Management Team. "He brings both established leadership and international business experience with him to the division," said Tjerk de Ruiter, CEO of Genencor. "Our goal is to be the growth engine of Industrial Biotechnology and Dr. Nedwin's experience and vision will certainly help us get there."

In addition to de Ruiter and Nedwin, the Genencor Senior Management Team includes James Laughton, Executive Vice President - Food & Feed; Philippe Lavielle, Executive Vice President - Business Development; Michael Arbige, PhD., Executive Vice President - Technology; Carole Cobb, Senior Vice President - Global Supply; Jim Sjoerdsma, Senior Vice President - Human Resources; and Andrew Ashworth, Vice President - Finance.

About Genencor

Genencor, a division of Danisco A/S, is a leader in the industrial biotechnology sector. In more than 40 countries, Genencor's 1,500 employees develop and market innovative enzymes and biobased solutions to improve the performance and reduce the environmental impact of a wide variety of industries, from laundry detergents to transportation fuels. Genencor also develops and produces enzymes for the food, beverage and animal nutrition industries, which are sold under the Danisco brand. In partnership with our customers, technology leaders and other stakeholders, Genencor's cutting-edge biotech platform provides competitive and sustainable solutions to the world, positioning Genencor as one of the leaders in the emerging biobased economy.


'/>"/>
SOURCE Genencor
Copyright©2007 PR Newswire.
All rights reserved

Related biology technology :

1. Sharon Ethanol appoints operations director
2. Kyron appoints former AMA chairman to board
3. Brady appoints GE efficiency expert as CTO
4. Merge Healthcare appoints new CEO, reports $215 million Q2 loss
5. Johnson Controls appoints Roell to head EOC
6. SecurePipe appoints two senior execs
7. Milwaukees PointOne appoints new president and CEO
8. Third Wave appoints new chairman
9. Midwest Venture Summit disappoints; Cato grades Midwest governors
10. Sonic Foundry appoints Engineering Dean and Cometa CEO to Board of Directors
11. TeraMEDICA Appoints Prekop as New President
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... ... June 23, 2016 , ... ... to announce the launch of their brand, UP4™ Probiotics, into Target stores nationwide. ... years, is proud to add Target to its list of well-respected retailers. This ...
(Date:6/23/2016)... -- Houston Methodist Willowbrook Hospital has signed a ... serve as their official health care provider. As ... provide sponsorship support, athletic training services, and most ... athletes and families. "We are excited ... to bring Houston Methodist quality services and programs ...
(Date:6/23/2016)... , June 23, 2016   EpiBiome , ... secured $1 million in debt financing from Silicon Valley ... up automation and to advance its drug development efforts, ... new facility. "SVB has been an incredible ... the services a traditional bank would provide," said Dr. ...
(Date:6/23/2016)... June 23, 2016 Apellis Pharmaceuticals, Inc. ... clinical trials of its complement C3 inhibitor, APL-2. ... multiple ascending dose studies designed to assess the ... subcutaneous injection in healthy adult volunteers. ... as a single dose (ranging from 45 to ...
Breaking Biology Technology:
(Date:6/22/2016)... 2016 On Monday, the Department of Homeland ... share solutions for the Biometric Exit Program. The Request ... Protection (CBP), explains that CBP intends to add biometrics ... the United States , in order to deter ... Logo - http://photos.prnewswire.com/prnh/20160622/382209LOGO ...
(Date:6/20/2016)... Securus Technologies, a leading provider of ... safety, investigation, corrections and monitoring announced that after ... secured the final acceptance by all three (3) ... Systems (MAS) installed. Furthermore, Securus will have contracts ... by October, 2016. MAS distinguishes between legitimate wireless ...
(Date:6/15/2016)... New York , June 15, 2016 /PRNewswire/ ... a new market report titled "Gesture Recognition Market by ... and Forecast, 2016 - 2024". According to the report, ... USD 11.60 billion in 2015 and is estimated ... reach USD 48.56 billion by 2024.  ...
Breaking Biology News(10 mins):